custom ad
NewsMay 26, 2021

Moderna said Tuesday its COVID-19 vaccine strongly protects children as young as 12, a step that could put the shot on track to become the second option for that age group in the U.S. With global vaccine supplies still tight, much of the world is struggling to vaccinate adults in the quest to end the pandemic. But earlier this month, the U.S. and Canada authorized another vaccine -- the shot made by Pfizer and BioNTech -- to be used starting at age 12...

By LAURAN NEERGAARD ~ Associated Press
A Chester County, Pennsylvania, Health Department employee, fills a syringe with Moderna COVID-19 vaccine before administering it to emergency medical workers and health care personnel at the Chester County Government Services Center on Dec. 29 in West Chester, Pennsylvania.
A Chester County, Pennsylvania, Health Department employee, fills a syringe with Moderna COVID-19 vaccine before administering it to emergency medical workers and health care personnel at the Chester County Government Services Center on Dec. 29 in West Chester, Pennsylvania.Matt Slocum ~ Associated Press, file

Moderna said Tuesday its COVID-19 vaccine strongly protects children as young as 12, a step that could put the shot on track to become the second option for that age group in the U.S.

With global vaccine supplies still tight, much of the world is struggling to vaccinate adults in the quest to end the pandemic. But earlier this month, the U.S. and Canada authorized another vaccine -- the shot made by Pfizer and BioNTech -- to be used starting at age 12.

Moderna aims to be next in line, saying it will submit its teen data to the U.S. Food and Drug Administration and other global regulators early next month.

The company studied more than 3,700 12- to 17-year-olds. Preliminary findings showed the vaccine triggered the same signs of immune protection in children as it does in adults, and the same kind of temporary side effects such as sore arms, headache and fatigue.

Receive Daily Headlines FREESign up today!

There were no COVID-19 diagnoses in those given two doses of the Moderna vaccine compared with four cases among children given dummy shots. In a news release, the company also said the vaccine appeared 93% effective two weeks after the first dose.

While children are far less likely than adults to get seriously ill from COVID-19, they represent about 14% of the nation's coronavirus cases. At least 316 have died in the U.S. , according to a tally by the American Academy of Pediatrics.

With plenty of vaccine supply in the U.S., younger teens flocked to get Pfizer's shot in the days after the FDA opened it to them, part of a push to get as many children vaccinated as possible before the next school year.

Pfizer and Moderna have begun testing in even younger children, from age 11 down to 6-month-old babies. This testing is more complex: Teens receive the same dose as adults, but researchers are testing smaller doses in younger children. Experts hope to see some results in the fall.

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education. The AP is solely responsible for all content.

Story Tags
Advertisement

Connect with the Southeast Missourian Newsroom:

For corrections to this story or other insights for the editor, click here. To submit a letter to the editor, click here. To learn about the Southeast Missourian’s AI Policy, click here.

Advertisement
Receive Daily Headlines FREESign up today!